Related Experiment Video
Updated: Jul 7, 2026
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
DNAzyme technology and cancer therapy: cleave and let die
Crispin R Dass1, Peter F M Choong, Levon M Khachigian
1Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Vic 3065, Australia. crispin.dass@svhm.org.au
Abstract:
Novel molecules are constantly being discovered and developed to find better means of managing debilitating and fatal diseases, which include cancer in its multiple forms. Among these molecules, and as a direct consequence of a better understanding of the molecular basis of diseases, are those falling within the class of gene therapeutics. Among these players, deoxyribozymes (DNAzymes) have come a long way from being just another analytic tool available to molecular biologists. Recent studies have shown the potential DNAzymes to serve as drugs both in cell-based assays and preclinical models of cancer. It is anticipated that with the development of smart delivery systems for DNAzymes, better pharmacokinetics and pharmacodynamics will be possible, expediting DNAzyme march toward the clinic. Also, the ability of DNAzymes to yield to such phenomena as light-induced activation may be exploited for targeted therapy. This review documents the rise of DNAzymes in the fight against cancer and serves as a forecast for this promising biotechnology in this context.
Insights
Deoxyribozymes (DNAzymes), a type of gene therapy, show promise as novel cancer drugs. Advancements in delivery systems and targeted activation could accelerate their clinical use.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Cancer remains a leading cause of death, driving the search for novel therapeutic molecules.
- Gene therapeutics, including deoxyribozymes (DNAzymes), are emerging as promising cancer treatment strategies.
- DNAzymes have evolved from analytical tools to potential therapeutic agents.
Purpose of the Study:
- To review the development and potential of DNAzymes as anti-cancer therapeutics.
- To forecast the future clinical applications of DNAzyme technology in oncology.
Main Methods:
- Review of recent studies on DNAzymes in cell-based assays and preclinical cancer models.
- Analysis of advancements in DNAzyme delivery systems and activation mechanisms.
Main Results:
- DNAzymes demonstrate significant potential in managing various cancer forms.
- Improved pharmacokinetics and pharmacodynamics are anticipated with advanced delivery systems.
- Light-induced activation offers potential for targeted cancer therapy.
Conclusions:
- DNAzymes represent a promising biotechnology for cancer treatment.
- Further development of delivery systems and targeted activation will be crucial for clinical translation.
- DNAzymes are poised to become a significant tool in the fight against cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...